College of Life Sciences, Shaanxi Normal University, 620 West Chang'an Avenue, Xi'an, Shaanxi 710119, China.
School of Medicine, Deakin University, Waurn Ponds, VIC 3216, Australia.
Life Sci. 2020 Jul 15;253:117740. doi: 10.1016/j.lfs.2020.117740. Epub 2020 May 3.
Annexin A2 (ANXA2) is closely associated with tumor malignancy and its N-terminus includes a vital domain for its function. The aims are to explore the correlation between the sites (Tyr23, Ser1, Ser11 and Ser25) in the domain and its roles.
We re-expressed ANXA2 with mutated sites in ANXA2-deleted human colonic adenocarcinoma cell line caco2 (ANXA2-/-caco2). A series of analyses were used to determine the correlation of each site with ANXA2 activation, cell malignancy enhancement and motility-associated microstructural development. Bioinformatics and luciferase reporter assays were employed to validate ANXA2-targeted miRNAs.
The in vitro results showed that all single and multiple mutations of the ANXA2 N-terminal sites inhibited ANXA2 phosphorylation at different levels and subsequently inhibited the proliferation, motility, and polymerization of F-actin and β-tubulin in caco2 cells. Motility-associated microstructures were significantly remodeled when these sites were mutated. The forced expression of miR-206 significantly suppressed the proliferation, motility and epithelial-mesenchymal transition (EMT) of caco2 cells. The in vivo results showed that all the ANXA2 N-terminal site mutations and forced expression of miR-206 significantly inhibited tumor growth. Overall, this study demonstrated that the sites of the ANXA2 N-terminus, especially Tyr23, play crucial roles in maintaining the high malignancy of colonic adenocarcinoma. Furthermore, miR-206 targets ANXA2 and plays a role as a cancer suppressor in colonic adenocarcinoma.
Our study provided evidence that further elucidates the molecular mechanism of ANXA2 and its roles in colonic adenocarcinoma and suggested potential targets of ANXA2 for colonic adenocarcinoma therapy by using miR-206 as a novel strategy.
膜联蛋白 A2(ANXA2)与肿瘤恶性程度密切相关,其 N 端包含一个对其功能至关重要的结构域。本研究旨在探讨该结构域中各位点(Tyr23、Ser1、Ser11 和 Ser25)与功能的相关性。
我们在 ANXA2 缺失的人结肠腺癌细胞系 caco2(ANXA2-/-caco2)中重新表达了带有突变位点的 ANXA2。采用一系列分析方法来确定各位点与 ANXA2 激活、细胞恶性增强和运动相关的微结构发育的相关性。生物信息学和荧光素酶报告基因检测用于验证 ANXA2 靶向的 miRNA。
体外实验结果表明,ANXA2 N 端各单点和多点突变不同程度地抑制了 ANXA2 的磷酸化,进而抑制了 caco2 细胞中 F-肌动蛋白和 β-微管蛋白的增殖、运动和聚合。当这些位点发生突变时,运动相关的微结构明显重塑。miR-206 的强制表达显著抑制了 caco2 细胞的增殖、运动和上皮间质转化(EMT)。体内实验结果表明,ANXA2 N 端各结构域突变和 miR-206 的强制表达均显著抑制了肿瘤的生长。综上所述,本研究表明,ANXA2 N 端的这些位点,尤其是 Tyr23,在维持结肠腺癌的高度恶性方面起着关键作用。此外,miR-206 靶向 ANXA2 并作为结直肠腺癌的一种抑癌因子发挥作用。
本研究提供了进一步阐明 ANXA2 分子机制及其在结肠腺癌中作用的证据,并提出了以 miR-206 为新策略治疗结肠腺癌的潜在 ANXA2 靶点。